Spyre Therapeutics
SYRE
SYRE
54 hedge funds and large institutions have $601M invested in Spyre Therapeutics in 2023 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
86% more funds holding
Funds holding: 29 → 54 (+25)
Holders
54
Holding in Top 10
3
Calls
$44K
Puts
–
Top Buyers
| 1 | +$52.2M | |
| 2 | +$34.8M | |
| 3 | +$30.8M | |
| 4 |
VA
VR Adviser
New York
|
+$28.6M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$26.9M |
Top Sellers
| 1 | -$1.67M | |
| 2 | -$829K | |
| 3 | -$827K | |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$399K |
| 5 |
YF
Yu Fan
|
-$348K |